Have documented disease progression following at least  and no more than  prior systemic regimens for advanced disease (nonresectable or metastatic). Subjects must have received at least  gemcitabine- or -FU-containing regimen for advanced cholangiocarcinoma. Subjects who have received systemic adjuvant chemotherapy will be permitted provided there is documented disease progression during or within  months of completing the therapy.
Patients may have received up to one prior systemic therapy for advanced or metastatic renal cell carcinoma with the exception of another VEGF inhibitor Food and Drug Administration (FDA)-approved for advanced RCC (i.e., pazopanib, bevacizumab, sorafenib or axitinib); if a patient develops metastatic disease within six months of discontinuation of adjuvant therapy, this will constitute one prior systemic therapy for advanced or metastatic renal cell carcinoma (RCC); if a patient develops metastatic disease and more than six months has elapsed since discontinuation of adjuvant therapy, this will not constitute prior systemic therapy for advanced or metastatic RCC; patients may have also received prior immunotherapy; patients must not have received a MET/hepatocyte growth factor (HGF) inhibitor or sunitinib as prior therapy; at least  days must have elapsed since completion of prior systemic therapy; patients must have recovered from all associated toxicities at the time of registration
Subjects with NPC must have received, or been intolerant to, a platinum-based combination as part of their prior therapy for advanced/metastatic disease;
Patients with esophageal cancer must have received, or been intolerant to, a platinum-based combination as part of their prior therapy for advanced/metastatic disease;
Patients with gastric cancer must have received, or been intolerant to, a fluoropyrimidine-platinum combination as part of their prior therapy for advanced/metastatic disease; Subjects in Part B must not have had more than  prior lines of cytotoxic chemotherapy;
In the dose escalation phase, the trial will be open for patients with stage IV or locally advanced unresectable gastrointestinal adenocarcinomas (gastric, cholangiocarcinoma, pancreatic, colorectal) who have failed at least one prior therapy; subjects must have received, and then progressed or been intolerant to, at least  standard treatment regimen in the advanced or metastatic setting
In dose expansion phase, Arm B will be open for  patients with colorectal adenocarcinoma; patients must have histologic diagnosis and metastatic disease and have not received prior irinotecan; patients must have received at least one prior line of standard treatment for locally advanced or metastatic disease
Have not received prior anti-cancer therapy for advanced or metastatic melanoma
Diagnosed with advanced or metastatic malignancy
For Part E dose confirmation: All participants must have histological evidence of locally advanced or metastatic triple negative breast cancer (TNBC) and prescreened mutations, amplification, or gene/protein expression alterations related to Notch pathway. Participants must not have received > lines of systemic treatment for advanced or metastatic TNBC.
Patients with only non-measurable bone lesions must have disease progression based on PCWG with  or more new lesions or have prostate-specific antigen (PSA) progression before enrollment. Arm : Patients with extensive-stage disease small cell lung cancer (SCLC) must meet the following criterion: i. Patients received ?  prior lines of therapy. Arm : Patients with HER-negative gastric or gastroesophageal junction cancer must meet the following criterion: i. Patients received ?  prior lines of therapy. Arm : Patients with locally advanced or metastatic urothelial (muscle-invasive bladder, ureter, urethra or renal pelvis) cancer must meet the following criterion: i. Patients received ?  prior lines of therapy in the advanced or metastatic disease setting. ii. Patients must have received prior platinum-based systemic chemotherapy. Arm : Patients with advanced or metastatic pancreatic adenocarcinoma must meet the following criteria: i. Patients must have received at least one line of platinum containing regimens in either an advanced or metastatic setting, unless the patient has known deleterious germline or somatic BRCA/ mutation prior to being screened (in which case they can be considered for the study if the patient has never received platinum-containing regimen), AND ii. Patients received ?  prior lines of therapy in the advanced or metastatic disease setting. Arm : Patients with advanced or metastatic solid tumor malignancies must meet the following criterion: i. Patients with at least  prior platinum-containing treatment in any treatment setting.
Subjects must have a diagnosis of measurable advanced or metastatic hepatocellular carcinoma; advanced HCC is defined as disease not amenable to surgery, ablation, transplant, or embolic therapy
Patients with NSCLC must have predominant squamous histology. Patients must have received prior therapy with a platinum-based treatment and a checkpoint inhibitor (CPI), if eligible, and should have received no more than  systemic regimens in the locally advanced or metastatic setting.
Received  or  prior standard of care regimens for advanced or metastatic disease
During Phase , subjects with advanced cancer who have received at least one prior therapy or are treatment naive, depending on the specified tumor type.
Cohort : Prior treatment with fulvestrant; Prior treatment with chemotherapy for advanced/metastatic disease; Any line(s) of therapy following treatment failure with a CDK / inhibitor in combination with an AI; Prior treatment with chemotherapy in the advanced/metastatic setting or with fulvestrant; Advanced/metastatic disease that is symptomatic and/or with visceral spread
Patients may have received any number of lines of prior systemic therapy for locally advanced/metastatic disease
(Part  only) Cohort : Have histologically or cytologically confirmed diagnosis of nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have not received prior systemic anticancer therapy for advanced or metastatic disease.
Advanced stage III, IV (NC, N) or surgically unresectable disease or disease that cannot be fully resected, obvious radiologic extracapsular spread (ECS), supraclavicular or matted metastatic disease, >  cervical nodes; (these patients will be placed on the quarterback trial due to advanced state of disease and poor prognostic features)
One of the following advanced solid malignancies** which qualifies for standard of care pembrolizumab treatment per Food and Drug Administration (FDA) approval:\r\n* Locally advanced or metastatic urothelial carcinoma that has progressed during or following platinum-based chemotherapy or within  months of neoadjuvant/adjuvant platinum-based therapy, ONLY in the second- or later-line setting\r\n* Unresectable or metastatic MSI-H or dMMR solid tumors that have progressed during or following prior treatment and have no satisfactory alternative treatment options (including MSI-H or dMMR colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan)\r\n* Recurrent locally advanced or metastatic, gastric or gastroesophageal junction (GEJ) adenocarcinoma expressing PD-L (as determined by an FDA-approved test) that have progressed on or after two or more systemic therapies, including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER/neu-targeted therapy\r\n**Patients who, due to the MSI-H or dMMR status of their disease, qualify for enrollment in more than one cohort (e.g. patients with MSI-H gastric adenocarcinoma) will be enrolled in the MSI-H/dMMR cohort
Have not received prior chemotherapy or targeted systemic therapy for their locally advanced inoperable or metastatic recurrence. Prior radiation therapy for recurrent disease is permitted
Patients with incurable, advanced or metastatic disease refractory to at least one previous line of therapy
Has pathologically confirmed metastatic pancreatic adenocarcinoma that has progressed after, at least, a first line of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed metastatic adenocarcinoma of the colon or rectum who have progressed to at least  lines of standard systemic chemotherapy for the metastatic disease, OR participants with pathologically confirmed locally advanced or metastatic sqEC that has progressed after at least a first line of standard systemic therapy for metastatic disease. First-line participants can be enrolled if a platinum doublet is contraindicated or refused by the participants, OR pathologically confirmed locally advanced or metastatic sqNSCLC that has progressed after at least  lines of standard systemic therapy for metastatic disease.
Patients with either a confirmed diagnosis of () metastatic colorectal cancer in liver based on histopathology of either a prior resection of primary lesion or a biopsied liver metastatic lesion; () advanced HCC (BCLC-stage C) with a characteristic  or -phase CT or dynamic contrast enhanced MRI finding showing arterial uptake followed by \washout\ of contrast in the venous-delayed phases per American Association for the Study of Liver Disease (AASLD) criteria; () metastatic gastric cancer; () metastatic NSCLC without EGFR or ALK mutation.
Patients can either be chemotherapy-naive or have received platinum-based chemotherapy for locally advanced or metastatic disease; acute effects of therapy must have resolved to baseline severity or to CTCAE grade =<  except for AEs that in the investigators judgment do not constitute a safety risk for the patient; patients who have received prior treatment with checkpoint inhibitors are eligible
Patients must not have received previous radiation therapy or investigational therapy for the treatment of advanced metastatic disease.
Patient who received any prior systemic hormonal therapy for advanced breast cancer; no more than one prior regimen of chemotherapy for the treatment of metastatic disease is permitted Note:
Patients who received ?  days of letrozole or anastrozole for advanced disease prior to inclusion in this trial are eligible.
Prior therapy\r\n* Arm A: Rebastinib plus paclitaxel: up to two prior non-taxane chemotherapy regimens for metastatic or incurable locally advanced disease permitted (no prior paclitaxel or eribulin); patients with estrogen receptor (ER)-positive disease are required to have relapse or progression on at least one line of endocrine therapy\r\n* Arm B: Rebastinib plus eribulin: up to three prior chemotherapy regimens for metastatic or incurable locally advanced disease permitted (no prior eribulin, but prior paclitaxel allowed): patients with ER-positive disease are required to have relapse or progression on at least one line of endocrine therapy
Have had disease progression, been refractory or intolerant to no more than  prior systemic regimens for locally advanced or metastatic pancreatic cancer. Participants who have received prior neoadjuvant therapy and who now have metastatic disease must have received  of the following for their metastatic disease: FOLFIRINOX, nanoparticle albumin-bound paclitaxel/gemcitabine, TS- (tegafur gimeracil oteracil potassium), irinotecan liposome injection/-fluorouracil (FU)/Leucovorin or single-agent gemcitabine prior to enrolment in this study.
Patients with solid tumors as described below:\r\n* Inoperable or metastatic (advanced) melanoma:\r\n** Has received, is intolerant, or refused a CTLA- inhibitor (ipilimumab) or a PD- inhibitor (nivolumab or pembrolizumab) as monotherapy and/or a combination of ipilimumab and nivolumab\r\n** Has received or is intolerant of a BRAF inhibitor or the combination of BRAF and MEK inhibitors for BRAFv mutant melanoma and a PD- inhibitor as monotherapy or in combination\r\n* Inoperable or metastatic (advanced) ovarian, primary peritoneal or fallopian tube carcinoma:\r\n** Has received platinum containing chemotherapy and has platinum refractory or resistant disease that has progressed on second line therapy\r\n** If platinum sensitive disease, should have received >=  lines of chemotherapy\r\n** May have received PARP inhibitors, bevacizumab or other targeted VEGF inhibitor therapy\r\n* Inoperable or metastatic (advanced) synovial sarcoma:\r\n** Should have received and progressed on >= two lines of systemic therapy\r\n* Subjects with other histologies:\r\n** Must have previously received two lines of systemic standard care (or effective salvage chemotherapy regimens) for metastatic disease, if known to be effective for that disease, and have been deemed either non-responders (progressive disease) or have recurred
Patients must not have received any systemic chemotherapy for advanced biliary cancer
Prior chemotherapy for advanced or metastatic disease
To be eligible for Cohorts -, patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease
To be eligible for Cohort , patients must not have received any systemic therapy for advanced/metastatic disease
Non-hepatocellular carcinoma subjects must have received at least  prior standard of care systemic anti-cancer therapy for their locally advanced or metastatic disease.
Arms , E, , E: patients who previously received >  lines of systemic chemotherapy for advanced or metastatic disease
All parts except Part B, Part E, and Part E dose expansion: Must have diagnosis of cancer that is advanced or metastatic
Part E dose expansion: must have cancer that is advanced or metastatic and have prior documentation of a mutation of PIKCA
Subjects who have received up to  lines of therapy for advanced disease, without prior exposure to taxane in the advanced stage setting
Progressed after the end of prior aromatase inhibitor therapy for advanced/metastatic breast cancer
Phase I only: Diagnosis of advanced/metastatic NSCLC for which no standard treatment option; Phase II only: Advanced NSCLC patients who have received at least  platinum-based systemic chemotherapy regimen
Diagnosis of advanced stage or metastatic HER-positive cancer with disease progressed after receiving at least one prior systemic therapy (immunohistochemistry or RT-PCR is used to determine HER positivity)
Dose Expansion: Histologically confirmed and documented, previously untreated or treated stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) having failed no more than  previous platinum containing chemotherapy regimen for locally advanced or metastatic disease or relapsed/refractory locally advanced or metastatic gastric adenocarcinoma having failed no more than  previous chemotherapy regimen for locally advanced or metastatic disease. Subjects with NSCLC who are known to be epidermal growth factor receptor (EGFR)-mutation positive must have received an EGFR inhibitor and subjects known to be anaplastic lymphoma kinase (ALK)-mutation positive must have received an ALK inhibitor. Prior to enrollment, confirmation of the following must be obtained:  Dose expansion - For subjects in the dose expansion portion of the study, it is mandatory that available archived tumor tissue in FFPE block or minimum  unstained consecutive core biopsy slides from  archival block that meet specific tissue requirements are available.
For Phase : Subjects who have advanced or metastatic disease as noted above that have received at least one prior therapy or have advanced or metastatic disease for which no curative treatment is available may be enrolled.
Subject must have received at least  prior systemic regimen for advanced or metastatic disease
Patients with advanced or metastatic breast cancer must have TNBC. Patients with advanced or metastatic disease may have received up to  lines of cytotoxic therapy. Adjuvant and/or neoadjuvant therapies are not counted in the number of lines of therapy. TNBC patients who have previously received platinum chemotherapy in the metastatic setting are allowed to enroll in the study as long as they did not progress while on or within  weeks from the day of the last platinum administration.
Has not received prior systemic treatment for their advanced/metastatic NSCLC.
Inclusion Criteria:\n\n        Among other criteria, patients must meet all of the following conditions to be eligible for\n        the study:\n\n          . Diagnosed with metastatic (i.e., cancer that has spread) TNBC\n\n               -  minimal or no expression of estrogen and progesterone receptors (ER/PR) <% of\n                  cells positive by immunohistochemistry\n\n               -  HER  staining  or + by IHC or copy number <. signals/cell\n\n          . Documented progression of disease based on radiographic, clinical or pathologic\n             assessment during or subsequent to the last anticancer regimen received.\n\n          . Breast cancer tumor confirmed to express gpNMB. This will be determined by submitting\n             a tissue sample from the advanced (locally advanced/recurrent or metastatic) disease\n             setting to a central laboratory for analysis.\n\n          . Received no more than two prior chemotherapy treatments for advanced (locally\n             advanced/recurrent or metastatic) breast cancer.\n\n          . Prior chemotherapy treatment must have contained an anthracycline (e.g. doxorubicin or\n             Doxil) if clinically indicated and a taxane (eg: Taxol).\n\n          . ECOG performance status of  - .\n\n          . Adequate bone marrow, liver and renal function.\n\n        Exclusion:\n\n        Among other criteria, patients who meet any of the following conditions are NOT eligible\n        for the study:\n\n          . Progression/recurrence of breast cancer during or within  months of completion of\n             neoadjuvant or adjuvant chemotherapy.\n\n          . Ongoing neuropathy or other chemotherapy or radiation-related toxicities that are\n             moderate (Grade ) or worse in severity.\n\n          . Known brain metastases, unless previously treated and asymptomatic for  months and\n             not progressive in size or number for  months.\n\n          . Significant cardiovascular disease.\n\n          . Previously received capecitabine and discontinued due to progression or intolerance;\n             previously received CDX- or other MMAE containing agents.\n\n          . Active systemic infection requiring treatment. Infection controlled by oral therapy\n             will not be exclusionary.\n\n          . Chronic use of systemic corticosteroids.
Inclusion Criteria - Cohort Expansion Phase:\n\n          -  Histologically-proven, unresectable, locally advanced or metastatic melanoma or NSCLC\n\n               -  Melanoma: Advanced or metastatic melanoma patients may be systemic therapy nave\n                  or may have received systemic treatment for unresectable locally advanced or\n                  metastatic disease. A patient who previously received systemic therapy must have\n                  had progression on a checkpoint inhibitor (e.g., anti-PD-L, anti-PD-,\n                  anti-CTLA-) as the most recent prior therapy.\n\n               -  NSCLC: NSCLC that has progressed during or following  or more prior systemic\n                  therapies for unresectable locally advanced or metastatic disease. Patients who\n                  are intolerant of, or have refused treatment with standard first line cancer\n                  therapy, will be allowed to enroll. Patients must not have had more than  prior\n                  systemic regimens (excluding experimental therapies) for unresectable locally\n                  advanced or metastatic disease.\n\n          -  B-H expression is not required for eligibility in this study; however, tumor\n             expression of B-H will be evaluated for all patients.\n\n          -  Measurable disease per RECIST . criteria\n\n          -  ECOG performance status  or \n\n          -  Acceptable laboratory parameters and adequate organ reserve.\n\n        Exclusion Criteria - Cohort Expansion Phase:\n\n          -  Patients with a history of symptomatic central nervous system metastases, unless\n             treated and asymptomatic\n\n          -  Patients with history of autoimmune disease with certain exceptions\n\n          -  History of allogeneic bone marrow, stem cell, or solid organ transplant\n\n          -  Treatment with systemic cancer therapy or investigational therapy within  weeks;\n             radiation within  weeks; trauma or major surgery within  weeks\n\n          -  History of clinically-significant cardiovascular disease; gastrointestinal\n             perforation; gastrointestinal bleeding, acute pancreatitis or diverticulitis within \n             weeks;\n\n          -  Active viral, bacterial, or systemic fungal infection requiring parenteral treatment\n             within  days; positive for human immunodeficiency virus or AIDS, hepatitis B or C.\n\n          -  Known hypersensitivity to recombinant proteins, polysorbate , or any excipient\n             contained in the drug or vehicle formulation for MGA or ipilimumab.
Have received no prior systemic chemotherapy for advanced/unresectable (inoperable) or metastatic urothelial cancer.
Part D: Patients may have received up to  previous line of chemotherapy and must have previously received  or more lines of endocrine therapy for advanced/metastatic breast cancer as a single agent or in combination. Patients must have received fulvestrant as one of the previous lines of endocrine therapy and have had documented progression while on, or within  month after the end of, fulvestrant therapy for advanced/metastatic breast cancer. Patients must have received prior treatment with a CDK/ inhibitor
Prior treatment with any type of systemic therapy for advanced disease.
For Part B (abemaciclib + gemcitabine): Any subtype. The participant must have received at least one but not more than three prior therapies for advanced/metastatic NSCLC.
For Part C (abemaciclib + ramucirumab): Any subtype. The participant must have received at least two but not more than three prior therapies for advanced/metastatic NSCLC.
For Part E (abemaciclib + pembrolizumab): Any subtype. The participant must have received at least one but no more than three prior therapies for advanced/metastatic NSCLC.
Subjects must have experienced disease progression or recurrence during or after at least one systemic therapy for advanced or metastatic disease
May have received prior therapies for advanced or metastatic disease
Prior therapy with more than one line of cytotoxic chemotherapy following diagnosis of advanced/metastatic disease, or disease which has progressed despite prior fulvestrant therapy.
Prior treatment with greater than (>)  cytotoxic chemotherapy regimen or > endocrine therapies for advanced or metastatic disease
Histologically-proven advanced/metastatic adenocarcinoma or squamous cell carcinoma of the esophagus or advanced/metastatic Siewert type  adenocarcinoma of the EGJ
Patients must have been treated with at least one prior systemic treatment for incurable advanced or metastatic SCCA of the anal canal; prior treatment for metastatic disease is not required for patients who develop new metastatic lesions during or within  months of completion of chemoradiation for limited-stage disease; patients who receive chemotherapy for incurable advanced or metastatic SCCA of the anal canal must wait a minimum >=  days ( weeks for nitrosoureas or mitomycin C) after the date of completion of chemotherapy prior to initiating treatment with nivolumab on this study; patients who undergo radiotherapy to a site of tumor must wait a minimum >=  months from the date of completion of radiotherapy prior to initiating treatment with nivolumab on this study
PHASE I: Patients may not have received >  prior chemotherapies for advanced disease
Advanced or metastatic cancer
Patients who received ?  days of letrozole or anastrozole for advanced disease prior to randomization are eligible.
Patients with metastatic or advanced-stage malignant tumor. Patients may have received up to  prior lines of chemotherapy for their metastatic disease
Patients must not have received any prior systemic therapy for metastatic or locally advanced colorectal cancer (CRC); prior VEGF inhibitors are not allowed
Advanced or metastatic disease
Patients with cytologically or histologically confirmed recurrent locally advanced or metastatic NSCLC have received at least one prior recognized systemic therapy for therapy for advanced disease, (recognized therapy must include a platinum doublet unless contraindicated due to organ dysfunction)
For Cohorts A and B, documented tumor progression (based on radiological imaging) after receiving at least one prior approved platinum-based chemotherapy regimen for advanced stage/metastatic NSCLC. An alternate chemotherapeutic agent/regimen is an acceptable substitute in the event that the subject was intolerant to, or ineligible to receive platinum based chemotherapy. Subjects enrolled in Cohort B cannot have more than  prior systemic treatments for advanced stage/metastatic NSCLC (neoadjuvant and adjuvant therapies are not counted in number of prior regimens and maintenance therapy is not counted as a separate regimen). Subjects in Cohort C will be required to have not received prior systemic anti-cancer therapies for metastatic disease (i.e., dabrafenib/trametinib will be st line treatment for metastatic disease);
Has had previous therapy for advanced/metastatic adenocarcinoma or squamous cell cancer of the esophagus or advanced/metastatic Siewert type  adenocarcinoma of the EGJ
Patients must have received at least one platinum-based chemotherapy for recurrent/advanced disease; recurrent disease is defined as having recurred after definitive therapy and advanced disease is defined as T and/or N and/or M; in addition, for completion of Cohort #, patients must also have received a tubulin inhibitor as part of their therapy for urothelial cancer; for purposes of this evaluation, treatment with chemotherapy regimens where carboplatin or similar is substituted for cisplatin or where a taxane is added or removed will be considered the same regimen; tubulin inhibitors in common use include paclitaxel, docetaxel, and vinblastine; the exception to this requirement applies to women
Received more than  prior regimen for advanced or metastatic disease.
Has received prior systemic treatment with a taxane for advanced/metastatic disease
Advanced metastatic disease
Initial diagnosis of advanced stage disease must have occurred ?  weeks prior to starting Cycle  Day . NOTE: The clock for this time interval starts with the date of last evaluation confirming advanced disease (either biopsy or imaging results).
Must have received one or two prior lines of systemic chemotherapy for advanced or metastatic disease, one of which must be a platinum-doublet therapy.
Received prior treatment with capecitabine or fluoropyrimidine for advanced or metastatic disease
Received more than  prior regimen for advanced or metastatic disease.
Previous systemic therapy for advanced or metastatic disease.
Received no prior chemotherapy for advanced or metastatic disease (Part  and Part a)
. Patients with advanced, recurrent or metastatic endometrial cancer who have received one chemotherapeutic regimen with platinum and taxane (either as adjuvant or as first line treatment) and who have progressed.
Histologic documentation of incurable, locally advanced or metastatic disease that has failed prior chemotherapy and for which no standard therapy exists, including the following: non-squamous NSCLC or non-mucinous and platinum-resistant ovarian cancer
Patients with advanced prostate cancer suitable for systemic treatment defined as: having metastatic disease, a biochemical relapse after primary therapy, or patients in whom primary therapy is not appropriate or feasible; patients without metastatic disease will need evaluation for local therapy and deemed inappropriate or have refused this treatment option
Key Inclusion Criteria\n\n        All Study Parts:\n\n          -  Diagnosis of cancer that has been histologically or cytologically confirmed\n\n          -  Eastern Cooperative Oncology Group Performance Status of  or \n\n        Part A ( of the following):\n\n          -  Ovarian cancer, triple-negative breast cancer, head and neck squamous cell cancer,\n             bladder cancer, metastatic colorectal cancer, pancreatic ductal adenocarcinoma, or\n             gastric cancer that is measurable or evaluable, nonmeasurable as defined by RECIST\n             v. and meets  of the following criteria:\n\n               -  is refractory to standard of care\n\n               -  no standard therapy available\n\n               -  patient refuses standard therapy\n\n          -  Advanced, unresectable, or metastatic melanoma with or without prior treatment and\n             measurable or evaluable, nonmeasurable disease as defined by RECIST v.\n\n          -  Advanced/metastatic PD-L-positive NSCLC (defined as a tumor proportion score [TPS] ?\n             %) with measurable or evaluable, non-measurable disease as defined by RECIST v. (\n             of the following):\n\n               -  ) No prior systemic chemotherapy if tumor does not have EGFR or ALK genomic\n                  aberrations\n\n               -  ) Disease progression on or after platinum-containing chemotherapy;\n\n               -  ) If tumor has EGFR or ALK genomic aberrations, disease progression on an\n                  FDA-approved therapy for EGFR or ALK genomic tumor aberrations\n\n        Phase  ( of the following):\n\n          -  Advanced/metastatic solid tumor with PD as defined by RECIST . or irRC on an\n             anti-PD-- or anti-PD-L-containing regimen as their most recent prior therapy\n\n          -  Advanced/metastatic epithelial ovarian cancer, peritoneal cancer or tubal cancer with\n             measurable disease as defined by RECIST ., that had progressed within  months of\n             completing ?  cycles of platinum-based therapy\n\n          -  Advanced/metastatic PDA that is locally advanced, unresectable or metastatic with\n             measurable disease as defined by RECIST v. in patients who have received at least\n             one prior line of systemic therapy for their disease\n\n        Key Exclusion Criteria\n\n          . Prior treatment as follows:\n\n               -  Part A: an immune CPI (e.g., PD-, PD-L, or cytotoxic T-lymphocyte antigen \n                  [CTLA-] inhibitor).\n\n             NOTE: For patients with melanoma, prior treatment with ipilimumab is allowed if it was\n             administered as adjuvant therapy and treatment was completed at least  months prior\n             to enrollment.\n\n               -  Phase :\n\n                    -  A CSF-R inhibitor or CSF- (or MCSF) inhibitor.\n\n                    -  prOVCA and PDA patients only: an immune CPI (e.g., PD-, PD-L, or CTLA-\n                       inhibitor)\n\n          . Symptomatic brain metastasis at screening\n\n          . Active autoimmune disease, documented history of autoimmune syndrome or disease, or a\n             chronic medical condition that requires chronic steroid therapy or immunosuppressive\n             medication\n\n          . History of pneumonitis or interstitial lung disease\n\n          . Severe, acute, or chronic medical or psychiatric condition or laboratory abnormality\n             that may increase the risk associated with study participation or study drug\n             administration or that may interfere with the interpretation of study results and, in\n             the judgment of the Investigator, would make the patient an inappropriate candidate\n             for the study\n\n          . Ocular melanoma
Advanced, incurable cancer
Pathologically confirmed locally advanced or metastatic disease per the treating institution's standard of care of the following tumor types: \r\n* Subjects with histologically confirmed locally advanced/unresectable or metastatic melanoma who meet all of the following criteria: \r\n** Subjects have received any number of prior lines of therapy or may be treatment naive \r\n** If the subject has been treated with a prior line of therapy, they must have had disease progression or be refractory to treatment OR \r\n* Subjects with histologically or cytologically confirmed locally advanced/unresectable or metastatic urothelial carcinoma (including mixed histologies of urothelial carcinoma with elements of other subtypes) of the renal pelvis, ureter, bladder or urethra (referred to broadly in this protocol as bladder cancer) who meet the following criteria: \r\n** Subjects must have disease progression or refractory disease after their prior line of therapy; subjects must have had at least  platinum based chemotherapy regimen for the treatment of metastatic or locally advanced unresectable disease; subjects may have received any number of prior lines of therapy OR \r\n** Subjects with disease recurrence within  year of a platinum based neoadjuvant or adjuvant therapy for bladder cancer OR \r\n** The subject actively refuses chemotherapy for the treatment of metastatic or locally advanced disease considered as standard treatment for this disease stage (i.e. a patient who has relapsed >  year after treatment with neoadjuvant or adjuvant chemotherapy), despite being informed by the investigator about the treatment options; the subjects refusal must be documented
Advanced periodontal disease (gum disease)
INCLUSION:\n\n        All Patients\n\n          . Male or female aged ? years.\n\n          . ECOG PS score of -.\n\n          . Adequate organ function.\n\n          . Ability to understand and willingness to sign informed consent form prior to\n             initiation of study procedures.\n\n          . Measurable disease per RECIST, OR for patients with a primary diagnosis of castration\n             resistant prostate cancer, progressive disease (PD) by prostate surface antigen (PSA)\n             or imaging in the setting of medical or surgical castration.\n\n          . Documented BRCA mutation, with the following exceptions: a) Patient is intended to be\n             enrolled in a Single-patient Cohort; b) Patient has an advanced DNA repair\n             mutation-positive solid tumor and is intended to be enrolled in Expansion Cohort .\n\n             Patients in the Dose-escalation Phase:\n\n          . Locally advanced solid tumor other than a primary central nervous system (CNS) tumor\n             for which the patient has received ? prior lines\n\n          . Confirmed solid tumor in one of the following categories:\n\n               -  BRCA mutation-positive pancreatic cancer for which the patient received up to \n                  prior line of cytotoxic chemotherapy in the advanced disease setting.\n\n               -  Advanced BRCA mutation-positive castration-resistant prostate cancer (CRPC) for\n                  which the patient received up to  prior lines of cytotoxic chemotherapy in the\n                  advanced disease setting.\n\n               -  Advanced BRCA mutation-positive ovarian cancer for which the patient received up\n                  to  prior lines of cytotoxic chemotherapy in the advanced disease setting.\n\n               -  Advanced BRCA mutation-positive triple-negative breast cancer (TNBC) for which\n                  the patient received up to  prior lines of cytotoxic chemotherapy in the\n                  advanced disease setting.\n\n               -  Advanced DNA repair mutation-positive solid tumors, including, but not limited to\n                  BRCA and non-BRCA DNA mutations, who have received up to  prior lines of\n                  cytotoxic chemotherapy in the advanced disease setting. DNA-repair mutations may\n                  include, but are not limited to ATM, CHEK, PALB, and RADD. Abnormal\n                  homologous repair deficiency (HRD) tests will also be allowed.\n\n        Note that in both dose escalation and dose expansion portions of the study, prior targeted\n        therapy including prior poly ADP ribose polymerase (PARP) inhibitor therapy, prior\n        immunotherapy, or prior hormonal therapy is permissible. Patients with castration resistant\n        prostate cancer may have received unlimited prior hormonal therapies.\n\n        EXCLUSION:\n\n          . History of leptomeningeal disease or spinal cord compression.\n\n          . Underwent major surgery within  weeks before first treatment.\n\n          . Received cancer-directed therapy  days ( weeks for mitomycin C and nitrosoureas)\n             before start of treatment.\n\n          . Grade  or greater peripheral neuropathy at start of treatment.\n\n          . If female, pregnant or breast-feeding.\n\n          . Known human immunodeficiency virus (HIV) infection or hepatitis B or C infection\n\n          . Any primary brain tumor (e.g., astrocytoma, glioblastoma).\n\n          . Hypersensitivity or history of anaphylactic reaction to any platinum-containing\n             agents.
Oncologists who do not have enough patients with advanced cancer
